Business
Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update
BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it will host a conference call and webcast on Thursday, March 25, 2021 at 4:30 p.m. ET to discuss a corporate update and results for the fourth quarter and full year 2020. Conference Call & Webcast DetailsDate:Thursday, March 25, 2021Time:4:30 pm Eastern TimeDomestic:877-407-0789International:201-689-8562Conference ID:13717079Webcast:https://investors.viridiantherapeutics.com/events/default.aspx A live webcast of the conference call can be accessed in the Investors section of Viridian Therapeutics website at https://investors.viridiantherapeutics.com About Viridian Therapeutics Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids Viridian is headquartered in Boulder, Colorado, with additional operations in Waltham, Massachusetts. Learn more about Viridian and our programs at www.viridiantherapeutics.com. Follow us on Twitter @ViridianThera and on LinkedIn. Contacts: InvestorsDan FerryLifeSci [email protected] MediaDarby PearsonVerge Scientific [email protected] \nSource: Viridian Therapeutics, Inc.","length":4194,"tagName":"div"}]